Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 10, 2005, Pages 1133-1139

  Michl, Patrick ^a,c   Downward, J ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c Abt Innere Medizin I und Endokrinologie   (Germany)

Author keywords

Akt; Apoptosis; Gastrointestinal; Metastasis; PI 3 kinase; Proliferation; Protein kinase B; Signaling; Survival; Tumor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CCAAT ENHANCER BINDING PROTEIN ALPHA; CELECOXIB; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; FLUOROURACIL; FOCAL ADHESION KINASE; GEFITINIB; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHA 665752; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PX 316; PX 866; SEMAXANIB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; WORTMANNIN;

ANGIOGENESIS; APOPTOSIS; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; METASTASIS; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; COLONIC NEOPLASMS; DNA REPAIR; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, EXPERIMENTAL; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 27744459507     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858638     Document Type: Review

References (88)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365
3. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100: 113-127
4. Fresno Vara JA, Casado E, de Castro J et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204
5. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev 2000; 14: 1027-1047
6. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-5037
7. Jones PF, Jakubowicz T, Pitossi FJ et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 1991; 88: 4171-4175
8. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991; 201: 475-481
9. Bellacosa A, Testa JR, Staal SP et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254: 274-277
10. Murthy SS, Tosolini A, Taguchi T et al. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet 2000; 88: 38-40
11. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657
12. Alessi DR, Caudwell FB, Andjelkovic M et al. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996; 399: 333-338
13. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004; 4: 235-256
14. Xu X, Sakon M, Nagano H et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 2004; 11: 25-32
15. Fujiwara Y, Hoon DS, Yamada T et al. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000; 91: 287-292
16. Kawamura N, Nagai H, Bando K et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999; 90: 413-418
17. Lee YI, Kang-Park S, Do SI et al. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 2001; 276: 16 969-16 977
18. Chung TW, Lee YC, Ko JH et al. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 2003; 63: 3453-3458
19. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125
20. Street A, Macdonald A, Crowder K et al. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004; 279: 12 232-12 241
21. Desbois-Mouthon C, Van Blivet-Eggelpoel MJ, Beurel E et al. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 2002; 36: 1528-1536
22. Vejchapipat P, Tangkijvanich P, Theamboonlers A et al. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004; 39: 1182-1188
23. Suzuki A, Hayashida M, Kawano H et al. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32: 796-802
24. Wang SY, Chen B, Zhan YQ et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004; 41: 267-273
25. Chen RH, Chang MC, Su YH et al. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 1999; 274: 23 013-23 019
26. Factor V, Oliver AL, Panta GR et al. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology 2001; 34: 32-41
27. Wang GL, Iakova P, Wilde M et al. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev 2004; 18: 912-925
28. Mottet D, Dumont V, Deccache Yet al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 2003; 278: 31 277-31 285
29. Arsham AM, Plas DR, Thompson CB et al. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 2004; 64: 3500-3507
30. Qi HL, Zhang Y, Ma J et al. Insulin/protein kinase B signalling pathway upregulates metastasis-related phenotypes and molecules in H7721 human hepatocarcinoma cell line. Eur J Biochem 2003; 270: 3795-3805
31. Nakanishi K, Sakamoto M, Yasuda J et al. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62: 2971-2975
32. Nakanishi K, Sakamoto M, Yamasaki S et al. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-312
33. Leng J, Han C, Demetris AJ et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756-768
34. Cheng J, Imanishi H, Liu W et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004; 95: 666-673
35. Senior K. COX-2 inhibitors: cancer prevention or cardiovascular risk? Lancet Oncol 2005; 6: 68
36. Yamamoto S, Tomita Y, Hoshida Y et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850
37. Schlieman MG, Fahy BN, Ramsamooj R et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115
38. Miwa W, Yasuda J, Murakami Y et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996; 225: 968-974
39. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641
40. Ruggeri BA, Huang L, Wood M et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998; 21: 81-86
41. Asano T, Yao Y, Zhu J et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580
42. Okami K, Wu L, Riggins G et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998; 58: 509-511
43. Tanno S, Mitsuuchi Y, Altomare DA et al. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001; 61: 589-593
44. Veit C, Genze F, Menke A et al. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 2004; 64: 5291-5300
45. Duxbury MS, Ito H, Benoit E et al. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003; 311: 786-792
46. Duxbury MS, Ito H, Benoit E et al. Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 2004; 23: 5834-5842
47. Duxbury MS, Ito H, Zinner MJ et al. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004; 198: 953-959
48. Fahy BN, Schlieman M, Virudachalam S et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89: 391-397
49. Bondar VM, Sweeney-Gotsch B, Andreeff M et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997
50. Ng SSW, Tsao MS, Chow S et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455
51. Ng SS, Tsao MS, Nicklee T et al. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-3275
52. Min Y, Adachi Y, Yamamoto H et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003; 63: 6432-6441
53. Stoll V, Calleja V, Vassaux G et al. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 2005; 54: 109-116
54. Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Inhibition of the phosphatidylinositol 3′-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003; 7: 354-363
55. Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the anti-proliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 2002; 62: 7372-7376
56. Grewe M, Gansauge F, Schmid RM et al. Regulation of cell growth and cyclin Dl expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581-3587
57. Stephan S, Datta K, Wang E et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004; 10: 6993-7000
58. Byun DS, Cho K, Ryu BK et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003; 104: 318-327
59. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-291
60. Christensen JG, Schreck R, Burrows J et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63: 7345-7355
61. Shinomiya N, Gao CF, Xie Q et al. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 2004; 64: 7962-7970
62. Baoping Y, Guoyong H, Jieping Y et al. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig Dis Sci 2004; 49: 948-953
63. Zinda MJ, Johnson MA, Paul JD et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001; 7: 2475-2479
64. Roy HK, Olusola BF, Clemens DL et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23: 201-205
65. Jiang YA, Fan LF, Jiang CQ et al. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J Gastroenterol 2003; 9: 491-494
66. Zhou XP, Loukola A, Salovaara R et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002; 161: 439-447
67. Sheng H, Shao J, Townsend CM Jr et al. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003; 52: 1472-1478
68. Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-7429
69. Khaleghpour K, Li Y, Banville D et al. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25: 241-248
70. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554
71. Sasaki T, Irie-Sasaki J, Horie Yet al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 2000; 406: 897-902
72. Sekharam M, Zhao H, Sun M et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003; 63: 7708-7716
73. Venkateswarlu S, Dawson DM, St Clair P et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002; 21: 78-86
74. Windham TC, Parikh NU, Siwak DR et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-7807
75. Bates RC, Edwards NS, Burns GF et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001; 61: 5275-5283
76. Bao S, Ouyang G, Bai X et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5: 329-339
77. Medema RH, Kops GJ, Bos JL et al. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404: 782-787
78. Schmidt M, Fernandez de Mattas S, van der Horst A et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22: 7842-7852
79. Wang Q, Wang X, Hernandez A et al. Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology 2001; 120: 1381-1392
80. Wang Q, Wang X, Hernandez A et al. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002; 277: 36602-36610
81. Jansen BJ, van Ruissen F, Cerneus S et al. Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. J Invest Dermatol 2003; 121: 1433-1439
82. Carter JH, Douglass LE, Deddens JA et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004; 10: 3448-3456
83. Adachi Y, Lee CT, Coffee K et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002; 123: 1191-1204
84. Bianco C, Tortora G, Bianco R et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8: 3250-3258
85. Ihle NT, Williams R, Chow S et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-772
86. Meuillet EJ, Ihle N, Baker AF et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004; 14: 513-527
87. Arico S, Pattingre S, Bauvy C et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-27621
88. Seeliger H, Guba M, Koehl GE et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004; 10: 1843-1852